Altogether, the decrease in the number of exacerbations, both in eosinophilic and neutrophilic asthma, was impressive.
The mode of action of macrolides in long-term therapy is a subject of a controversial debate. Antibiotic effects do not seem to play a significant role, especially not against Pseudomonas, which is naturally resistant against macrolides. Antiinflammatory effects, especially inhibitory effects on tumor necrosis factor a and IL-8, could be demonstrated, but they were not dramatic and not more pronounced than, for example, the effects of inhaled steroids (11) . An increase in gastrointestinal motility followed by a decrease in gastroesophageal reflux is known for macrolides, but it does not seem likely that this explains the huge effects of macrolides on exacerbation alone.
The substudy of the AMAZES trial published in this issue of the Journal by Taylor and colleagues (pp. 309-317) (12) investigates a different mechanism of action. A significant reduction in the diversity of the respiratory microbiome directly associated with the reduction of the exacerbation rate could be demonstrated. The decrease in diversity is essentially a result of a reduction of Haemophilus spp. in the respiratory microbiome. The downregulation of bacterial gene expression responsible for the formation of biofilms that prevent Haemophilus from being attacked by the immune response could be an explanation for this. This mechanism, known as quorum-sensing antagonistic activity, also had been discussed for Pseudomonas spp., and is in line with the macrolide effects in cystic fibrosis and bronchiectasis (13) .
The study has a number of strengths. It is a prospective randomized controlled study, and the microbiome workup had been performed according to established and worldwide accepted standards. Nevertheless, the study results leave me helpless. The decrease in microbiome diversity has been shown to be detrimental with regard to the long-term prognosis in different diseases. The subgroup analysis of the BLESS study in bronchiectasis showed that the reduction of Haemophilus spp. opens a niche that is later filled by Pseudomonas, the most important parameter for disease deterioration over the long term (14) . The increase of macrolide resistance is not good news. Although Streptococcus viridans is predominantly affected, a transmission of resistance genes to other pathogens by plasmid transfer could create a rapid increase in resistances in many pathogens (15) .
The work published here shows that the respiratory microbiome and its integrity seem to be important factors to prevent exacerbations of chronic respiratory diseases, including asthma. The respiratory microbiome is directly related to the gastrointestinal microbiome. The potential of several measures, ranging from nutritional supplementation to stool transplantation, to restore a pathologic gastrointestinal microbiome has been recently demonstrated. Whether this has an effect on the airway microbiome remains unclear, but it seems to be very likely. There is no doubt that antibiotics affect both the gastrointestinal and the respiratory microbiome. However, in the age of a worldwide increase in antibiotic resistance, it is questionable whether the broad use of antibiotics as maintenance treatment for chronic diseases is a wise decision, as antibiotic resistance is closely correlated to infectious disease-related mortality. King Arthur and the Knights of the Round 
